Analyst consensus rating
BeOne Medicines Analyst Rating: Strong Buy
Direct answer
BeOne Medicines's consensus rating is Strong Buy.
27 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $436.46.
Forecast evidence checked October 18, 2026.
Get free BeOne Medicines email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $369.06
- Average price target
- $436.46
- High price target
- $528.00
- Low price target
- $370.00
- Low target gap
- +0.3%
- Target upside
- +18.3%
- High target gap
- +43.1%
- Target range width
- 42.8%
- Consensus rating
- Strong Buy
- Analysts
- 27
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BeOne Medicines?
BeOne Medicines has a verified Strong Buy consensus. The same dataset has an average price target of $436.46.
How far are BeOne Medicines's low and high targets from the recorded price?
The low target implies +0.3%, while the high target implies +43.1%.
How many analysts are included in BeOne Medicines's consensus?
The verified consensus includes 27 analysts.
How is BeOne Medicines's target upside or downside calculated?
The average target of $436.46 is divided by the recorded price of $369.06, then one is subtracted to produce +18.3%. This does not guarantee a future return.
When was BeOne Medicines's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.